Previous 10 | Next 10 |
MALVERN, Pa. and SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of A...
The European Medicines Agency has granted PRIME status to PhaseBio Pharmaceuticals' ( PHAS -2.1% ) PB2452 as a reversal agent of AstraZeneca's ( AZN ) anticoagulant Brilinta (ticagrelor). More news on: PhaseBio Pharmaceuticals, Inc., AstraZeneca PLC, Healthcare stocks news, Read ...
PB2452 granted PRIME Designation by the European Medicines Agency PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase 2a clinical trials, PB2452 provided immediate and sustained reversal of the antiplatelet effects of ticag...
MALVERN, Pa. and SAN DIEGO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced presentation of d...
Gainers: BGFV +28.1% . MX +14.5% . ICHR +11.9% . MMSI +8.2% . PHAS +6.9% . More news on: Big 5 Sporting Goods Corporation, MagnaChip Semiconductor Corporation, Ichor Holdings, Ltd., Stocks on the move, , News on ETFs Read more ...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) inks an agreement with Viamet Pharmaceuticals Holdings and its wholly owned subsidiary Selenity Pharmaceuticals to acquire all of their assets and intellectual property related to certain aldosterone synthase inhibitors including lead candidate SE-6...
MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that it has signed an agr...
January 13, 2020 Palm Beach, FL –January 13, 2020 – Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2% over the f...
Gainers: Sorrento Therapeutics (NASDAQ: SRNE ) +38% . More news on: Sorrento Therapeutics, Inc., Ultragenyx Pharmaceutical Inc., Venus Concept Inc., Stocks on the move, Read more ...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) is up 12% premarket on announcing financing and co-development collaboration with SFJ Pharmaceuticals for the development of PB2452, a reversal agent for the antiplatelet therapy ticagrelor. More news on: PhaseBio Pharmaceuticals, Inc....
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...